| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
3-O-Methyl-DL-DOPA targets the catecholamine metabolic pathway. As the O-methylated metabolite of L-DOPA formed via COMT, it is involved in the metabolism of dopamine and other catecholamines. Its "target" in research is the study of catecholamine metabolism, epilepsy, and amino acid decarboxylase deficiency.
|
|---|---|
| ln Vitro |
Endogenous metabolites are those that the Kyoto Encyclopedia of Genes and Genomes has identified as products or substrates of the approximately 1900 metabolic enzymes that are encoded in human genome. Numerous of these metabolites have been shown to have harmful effects, as evidenced by the body of literature [1].
In vitro, 3-O-Methyl-DL-DOPA is used to study catecholamine metabolism and the activity of COMT. It is an endogenous metabolite present in cerebrospinal fluid. Its activity is studied in cell-free systems and cell cultures to investigate the regulation of catecholamine metabolism. |
| ln Vivo |
In vivo, 3-O-Methyl-DL-DOPA is an endogenous metabolite present in cerebrospinal fluid. It is formed from L-DOPA via COMT. It can be used for the research of epilepsy, purine nucleoside phosphorylase deficiency, and aromatic L-amino acid decarboxylase deficiency.
|
| Enzyme Assay |
In vitro enzyme assays with 3-O-Methyl-DL-DOPA typically involve studying COMT activity. The compound is used as a product in assays to measure enzyme activity. Standard assays involve incubating L-DOPA with COMT enzyme preparations and measuring the formation of 3-O-methyl-DL-DOPA by HPLC or LC-MS.
|
| Cell Assay |
In vitro cell culture experiments with 3-O-Methyl-DL-DOPA involve treating neuronal cells or other cell types to study catecholamine metabolism. Cells are treated with the compound, and endpoints include assessment of COMT activity, dopamine levels, and metabolic changes. These experiments characterize the role of 3-O-methyl-DL-DOPA in catecholamine metabolism.
|
| Animal Protocol |
In vivo animal experiments with 3-O-Methyl-DL-DOPA typically involve measuring its levels in cerebrospinal fluid or brain tissue as a biomarker of catecholamine metabolism. Animal models of epilepsy or amino acid decarboxylase deficiency are used to study changes in 3-O-methyl-DL-DOPA levels and their correlation with disease states.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 3-O-Methyl-DL-DOPA reflect its role as a metabolite. It is formed from L-DOPA and is present in cerebrospinal fluid. Its levels reflect catecholamine metabolism and may be altered in neurological disorders. Specific PK data are not available as it is a metabolite rather than a drug.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
Methoxytyrosine is one of the main biochemical markers of aromatic L-amino acid decarboxylase deficiency, a congenital metabolic defect that affects the biosynthesis of serotonin and dopamine. Elevated levels of 3-methoxytyrosine are found in cerebrospinal fluid, plasma, and urine. Catechol-O-methyltransferase, the enzyme responsible for the production of 3-methoxytyrosine, is derived from levodopa in many organs. However, its half-life (approximately 15 hours) is longer than that of levodopa (approximately 1 hour). This means it accumulates in the plasma and brain tissue of patients receiving long-term levodopa treatment (e.g., those with Parkinson's disease). 3-Methoxytyrosine has some influence on levodopa-related motor dysfunction, including inhibiting striatal tyrosine uptake, competing with levodopa for transport along the blood-brain barrier, and inhibiting dopamine release. 3-Methoxytyrosine also increases homocysteine levels, an amino acid that can induce cardiovascular disease and neuronal damage. Other toxic effects may include oxidative DNA damage (which can lead to cell death), decreased motility, and reduced mitochondrial membrane potential. (Wikipedia) 3-O-Methyl-DL-DOPA has a low toxicity profile as a naturally occurring metabolite. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. Comprehensive toxicology studies have not been published for this compound. |
| References |
|
| Additional Infomation |
3-Methoxytyrosine is a derivative of tyrosine. It is one of the main biochemical markers of aromatic L-amino acid decarboxylase deficiency (AADC, EC 4.1.1.28), a congenital metabolic defect that affects the biosynthesis of serotonin and dopamine. Patients are usually diagnosed in infancy due to developmental delays, hypotonia, and extrapyramidal motor dysfunction. Diagnosis is based on abnormal neurotransmitter metabolite profiles in cerebrospinal fluid and decreased AADC activity in plasma. Elevated levels of 3-methoxytyrosine are found in cerebrospinal fluid, plasma, and urine. (A3381, A3382, A3383)
3-O-Methyl-DL-DOPA (3-Methoxytyrosine) is the O-methylated metabolite of levodopa (L-DOPA) formed via catechol-O-methyltransferase (COMT). It is an endogenous metabolite present in cerebrospinal fluid. It can be used for the research of epilepsy, purine nucleoside phosphorylase deficiency, and aromatic L-amino acid decarboxylase deficiency. The compound is not a drug and has no therapeutic indications. |
| Molecular Formula |
C10H13NO4
|
|---|---|
| Molecular Weight |
211.21
|
| Exact Mass |
211.084
|
| CAS # |
7636-26-2
|
| Related CAS # |
3-O-Methyldopa;300-48-1
|
| PubChem CID |
1670
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
407.3±45.0 °C at 760 mmHg
|
| Flash Point |
200.1±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
0.08
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)CC(C(=O)O)N)O
|
| InChi Key |
PFDUUKDQEHURQC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)
|
| Chemical Name |
2-amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7346 mL | 23.6731 mL | 47.3462 mL | |
| 5 mM | 0.9469 mL | 4.7346 mL | 9.4692 mL | |
| 10 mM | 0.4735 mL | 2.3673 mL | 4.7346 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
